If you used Dupixent and were later diagnosed with cutaneous T-cell lymphoma or another T-cell lymphoma, you may qualify for compensation.
Dupixent (dupilumab) is a biologic injection made by Regeneron and Sanofi, prescribed for atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, and several other inflammatory conditions. Lawsuits allege that Dupixent use is linked to the development or acceleration of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) — rare cancers that affect white blood cells — and that patients weren't adequately warned of this risk.
In June 2026, the U.S. Judicial Panel on Multidistrict Litigation consolidated the federal Dupixent cases into a new MDL in the District of New Jersey, before Judge Zahid N. Quraishi, transferring the first wave of pending cases and identifying additional related lawsuits for future consolidation. The litigation is structured as an MDL rather than a class action, meaning each plaintiff's case and compensation is evaluated individually.
Here's what happens after you reach out:
A short set of free eligibility questions about your situation — takes about two minutes.
Our network reviews your answers against current qualifying criteria and reaches out if you may qualify.
You decide whether to move forward. There's never a cost to check your eligibility.
Filing deadlines vary by state and depend on when your diagnosis was made. With the federal cases now consolidated into an MDL and more claims being identified for transfer, it's worth checking with an attorney about your specific timeline sooner rather than later.
The Judicial Panel on Multidistrict Litigation centralized federal Dupixent T-cell lymphoma lawsuits into MDL No. 3180 in New Jersey on June 4, 2026, consolidating 15 transferred cases before Judge Zahid N. Quraishi.
Read more →Get updates on Dupixent, plus other case types we cover.
We'll keep you updated on Dupixent and other case types.